STEMI - ST-segment Elevation Myocardial InfarctionNCT07382700
Metabolic Characteristics of Plasma OxPLs in STEMI Patients.
An observational study of STEMI - ST-segment Elevation Myocardial Infarction, run by First Affiliated Hospital of Ningbo University at 1 site in China.
Trial summary
The goal of this observational study is to investigate the structural composition and metabolic characteristics of OxPLs in ST-segment elevation myocardial infarction(STEMI) patients. Explore OxPLs characteristic fingerprint biomarkers from different populations and analyze OxPLs fingerprint spectra. Read more about this study
- Who is it for?
- Ages 50 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- STEMI - ST-segment Elevation Myocardial Infarction
- How many people
- 240 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2025to 31 Dec 2027
- How long will I take part?
- 1 Year
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: STEMI patients admitted to our cardiovascular department for concurrent PCI surgery between January 2025 and December 2025.
Who may be able to join
- The patient meets the diagnostic criteria for STEMI (refer to the "Diagnosis and Treatment Guidelines for Acute ST Segment Elevation Myocardial Infarction (2021)")
- Agree to perform direct PCI
- The onset time is less than 12 hours and successfully undergoing emergency PCI treatment
- After admission, all STEMI patients are routinely treated with antiplatelet aggregation, anticoagulation, lipid-lowering, and anti myocardial remodeling drugs.
Who cannot join
- Previous history of myocardial infarction
- Accompanied by other cardiovascular diseases, such as severe heart valve disease, severe heart failure, congenital heart disease, cardiomyopathy, etc
- Merge with severe infection
- Merge with severe anemia
- Merge with severe liver and kidney dysfunction
- Combined with malignant tumors
Show all 10Show fewer
- Accompanied by a history of autoimmune or hematological diseases
- Recent history of severe trauma or surgery
- Patients with incomplete clinical data
- The patient does not agree to undergo data collection
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, 315010
About this study
Official title: Metabolic Characteristics of Plasma OxPLs in ST-segment Elevation Myocardial Infarction Patients and Its Value Analysis in Predicting Major Adverse Cardiovascular Events Risk After Percutaneous Coronary Intervention Surgery.
The goal of this observational study is to investigate the structural composition and metabolic characteristics of OxPLs in ST-segment elevation myocardial infarction(STEMI) patients. Explore OxPLs characteristic fingerprint biomarkers from different populations and analyze OxPLs fingerprint spectra. Based on the OxPLs fingerprint of STEMI patients, a machine learning classifier is used to establish an artificial intelligence assisted post PCI major adverse cardiovascular events risk prediction system, achieving the transformation of basic research into clinical application.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthy Group | Healthy people | |
| Coronary Artery Disease Group | Stable coronary heart disease patient | |
| STEMI-M | Male patients with ST segment elevation myocardial infarction | |
| STEMI-F | female patients with ST segment elevation myocardial infarction |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2026
- Study start1 Jan 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for STEMI - ST-segment Elevation Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 240 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- First Affiliated Hospital of Ningbo University
- Sponsor type
- Research network
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07382700
- Sponsor's protocol ID
- 2025004A
- Status last verified
- Jan 2026
- First submitted
- 27 Jan 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No